Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults.

Althoff KN, McGinnis KA, Wyatt CM, et al. Clin Infect Dis. 2015;60(4):627-638.

Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results.

Arribas JR, Thompson M, Sax PE, et al. J Acquir Immune Defic Syndr. 2017;75(2):211-218.

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.

Boyd MA, Mocroft A, Ryom L, et al. PLoS Med. 2017;14(11):e1002424.

Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals.

Brown TT, Chen Y, Currier JS, et al. J Acquir Immune Defic Syndr. 2013;63(3):323-330.

Management of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapy.

Burgess MJ, Zeuli JD, Kasten MJ. HIV AIDS. 2015;7:251-264.

Kidney diseases associated with human immunodeficiency virus infection.

Cohen SD, Kopp JB, Kimmel PL. N Engl J Med. 2017;377(24):2363-2374.

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Clin Infect Dis. 2010;51(5):496-505.

Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment.

DeJesus E, Haas B, Segal-Maurer S, et al. AIDS Res Hum Retroviruses. 2018;34(4):337-342.

Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis.

Erqou S, Lodebo BT, Masri A, et al. JACC Heart Fail. 2019;7(2):98-108.

Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial.

Hoy JF, Grund B, Roediger M, et al. J Bone Miner Res. 2017;32(9):1945-1955.

Initiation of antiretroviral therapy in early asymptomatic HIV infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. New Engl J Med. 2015;373(9):795-807.

Factors associated with chronic renal failure in HIV-infected ambulatory patients.

Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI, McGwin GJ, HIV Outpatient Study Group. AIDS. 2004;18(16):2171-2178.

Vascular disease and aging in HIV: time to extend the treatment cascade.

Longenecker CT. Vasc Med. 2018;23(5):476-477.

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.

Ma Q, Vaida F, Wong J, et al. J Neurovirol. 2016;22(2):170-178.

Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap.

McArthur JC, Steiner J, Sacktor N, Nath A. Ann Neurol. 2010;67(6):699-714.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, et al. Lancet HIV. 2018;5(5):e211-e220.

Screening for anal cancer in women.

Moscicki AB, Darragh TM, Berry-Lawhorn JM, et al. J Low Genit Tract Dis. 2015;19(3 Suppl 1):S27-42.

Ageing and inflammation in patients with HIV infection.

Nasi M, De Biasi S, Gibellini L, et al. Clin Exp Immunol. 2017;187(1):44-52.

Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. AIDS. 2016;30(2):273-291.

The hidden burden of fractures in people living with HIV.

Premaor MO, Compston JE. JBMR Plus. 2018;2(5):247-256.

Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study.

Rasmussen LD, May MT, Kronborg G, et al. Lancet HIV. 2015;2(7):e288-298.

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.

Sax PE, Zolopa A, Brar I, et al. J Acquir Immune Defic Syndr. 2014;67(1):52-58.

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment.

Saylor D, Dickens AM, Sacktor N, et al. Nat Rev Neurol. 2016;12(4):234-248.

Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.

Torres HA, Rallapalli V, Saxena A, et al. Clin Microbiol Infect. 2014;20(10):O672-O679.

HIV and ischemic heart disease.

Vachiat A, McCutcheon K, Tsabedze N, Zachariah D, Manga P. J Am Coll Cardiol. 2017;69(1):73-82.

Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications.

Wiggins BS, Lamprecht DG, Jr., Page RL, 2nd, Saseen JJ. Am J Cardiovasc Drugs. 2017;17(5):375-389.

HIV and aging.

Wing EJ. Int J Infect Dis. 2016;53:61-68.